Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

iStent Inject in phakic open-angle glaucoma

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Glaucoma II

Session Date/Time: Tuesday 08/09/2015 | 08:00-10:30

Paper Time: 08:12

Venue: Room 17

First Author: : M.Klamann GERMANY

Co Author(s): :    J. Gonnermann   M. Pahlitzsch   A. Maier   N. Torun   E. Bertelmann        

Abstract Details


The effectiveness and complication profile of the iStent inject implantation among different phakic open angle glaucoma subgroups were analyzed.


Department of Ophthalmology, University Medicine Charité Berlin, Berlin, Germany.


In this retrospective cohort outcome study, 32 consecutive phakic patients suffering from glaucoma (primary open angle glaucoma (POAG) N = 17; pseudoexfoliation glaucoma (PEX) N = 15) were treated with the iStent inject. The intraocular pressure (IOP) and the number of antiglaucoma medication before and after surgery were evaluated.


In POAG, mean IOP at 6 months measured 14.19 ± 1.38 mmHg with an average decrease of 33% from preoperative IOP (p<0.001), and 15.33 ± 1.07 mmHg with an average decrease of 35% in PEX (p<0.001), respectively. The number of antiglaucoma medication significantly decreased from 2.19 ± 0.91 to 0.88 ± 0.62 in POAG (p<0.001) and from 2.33 ± 1.23 to 1.04 ± 0.30 in PEX (p<0.001) after 6 months


In conclusion, implantation of the iStent inject has the ability to lower the postoperative IOP significantly in phakic POAG and PEX after a short follow-up of 6 months with a favorable risk profile.

Financial Interest:


Back to previous